Releases Details

Filing of Form 10-Q for Second Quarter

Aug 11, 2022
RNS Number : 6259V
MaxCyte, Inc.
11 August 2022





MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022



ROCKVILLE, MD, August 11, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended June 30, 2022.


A copy of the Form 10-Q is available to view on the SEC's website at and has also been posted to the "SEC filings" page of the Company's website,




MaxCyte Contacts:


US IR Adviser 

Gilmartin Group 

David Deuchler, CFA 

+1 415-937-5400 


US Media Relations


Valerie Enes


Nominated Adviser and Joint Corporate Broker 

Panmure Gordon 

Emma Earl / Freddy Crossley 

Corporate Broking 

Rupert Dearden 


+1 408-497-8568




+44 (0)20 7886 2500 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh



+44 (0)203 709 5700




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.